How much does semaglutide reduce hs-CRP — and what does that actually mean?

The misconception worth clearing up first: is the CRP drop just weight loss in disguise?

A reasonable assumption, and a common one. Losing body fat does reduce circulating inflammatory markers, adipose tissue, particularly visceral fat, actively secretes pro-inflammatory molecules, so less of it means less fuel for chronic inflammation. That mechanism is real. But the hs-CRP reductions seen in semaglutide trials appear larger than the weight lost would fully explain.

In the STEP 1 trial (68 weeks, semaglutide 2.4 mg versus placebo, nearly 2,000 adults with obesity) participants using semaglutide lost an average of around 15% of body weight and showed hs-CRP reductions of roughly 30–40% from their starting level. Statistical modelling in several analyses suggested the inflammatory reduction was only partially mediated by fat loss; a portion of the benefit remained after adjusting for the weight change. The SELECT cardiovascular outcomes trial (which enrolled over 17,500 adults with existing cardiovascular disease and overweight or obesity, but without diabetes) replicated the pattern. Participants on semaglutide saw meaningful hs-CRP reductions early in treatment, before substantial weight loss had occurred. That timing matters. It points toward a direct anti-inflammatory action through GLP-1 receptor signalling, not a delayed consequence of body-composition change.

So the misconception is understandable, but the evidence leans the other way: the hs-CRP drop is partly, not purely, the weight loss doing its job. The fuller picture on visceral fat changes with semaglutide adds another layer to that story.

What hs-CRP actually measures, and why these reductions matter clinically

C-reactive protein is a protein produced by the liver in response to inflammation anywhere in the body. The high-sensitivity assay (hs-CRP) detects lower concentrations and is used specifically to assess cardiovascular risk in people who appear otherwise healthy. A reading below 1 mg/L is considered low risk; 1–3 mg/L is intermediate; above 3 mg/L signals elevated risk. Many people living with obesity or metabolic syndrome sit in the intermediate-to-high range even without an acute illness, this is the chronic, low-grade inflammation that accumulates quietly over years.

Why does it matter? Elevated hs-CRP is an independent predictor of heart attack and stroke, over and above cholesterol levels and blood pressure. Bringing it down (by whatever mechanism) is thought to translate into real reductions in cardiovascular event risk. The SELECT trial put that hypothesis to a direct test: people on semaglutide had a 20% relative reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) compared with placebo. Whether the hs-CRP reduction contributed to that benefit, or was simply a parallel marker of the same underlying improvement, is still being studied. The SELECT trial's cardiovascular findings are worth reading in full if this is the angle you are researching. The STEP 1 paper published in the New England Journal of Medicine also contains the inflammation sub-analyses referenced above.

Where the research stands, and what it means for people considering semaglutide

The 30–40% hs-CRP reduction is a consistent signal across multiple trials, but some important caveats belong here. These are group averages; individual responses vary considerably depending on starting inflammation levels, the presence of other conditions, diet, activity and how much weight is ultimately lost. No trial has yet demonstrated that the hs-CRP reduction translates directly into a measurable reduction in mortality independent of the cardiovascular event data, that chain of causation is plausible but not yet fully proven.

Semaglutide is licensed in the UK for weight management under the brand name Wegovy (BMI 30 or above, or 27 and above with a weight-related health condition), and separately for reducing cardiovascular event risk in eligible adults. Wegovy is a prescription-only medicine, a prescriber assesses whether it is suitable for you based on your complete clinical picture, not hs-CRP alone. For context on what treatment involves, including realistic outcomes, the weight-loss percentages seen in Wegovy's clinical programme gives a grounded overview. The NHS medicines page for semaglutide covers the full licensed uses and known side effects in plain language.

If you are interested in what semaglutide's evidence base looks like more broadly (including how this inflammation data fits alongside weight and metabolic outcomes) the semaglutide overview pulls those threads together. For anyone looking at the cost side of private treatment, Wegovy pricing explained sets out what a clinically complete service actually includes. And if you have questions before taking any next step, the team at contact or the FAQs are there seven days a week.

At nume, every consultation is read the same day by a GPhC-registered Independent Prescriber, a real clinician, not an automated system. If semaglutide is clinically suitable, treatment is dispatched the same day and delivered free the next working day by DPD, in plain packaging. If you are ready to explore whether Wegovy is right for you, start your free consultation.